Indications for Use: ArioSeven™ is indicated for the control of bleeding and for the prevention of bleeding during surgical interventions and invasive procedures in the following patient groups:

• Patients with hereditary hemophilia who have inhibitors to coagulation factor VIII or IX with a titer >5 Bethesda Units (BU); 
• Patients with hereditary hemophilia who are expected to have an immune response to coagulation factor VIII or IX based on medical history; 
• Patients with acquired hemophilia; 
• Patients with congenital deficiency of coagulation factor VII; 
• Patients with Glanzmann's thrombasthenia who are refractory (currently or in the past) to platelet transfusion, with or without platelet antibodies, or when platelet transfusion is unavailable.
  

ArioSeven™ is also used for the prevention of bleeding in patients with hereditary hemophilia who have inhibitors to coagulation factor VIII or IX with a titer >5 BU or who are expected to have an immune response to coagulation factor VIII or IX based on medical history.

This product is included in the  Essential Drug List (EDL).

Prescription Status: Rx only.

CONTRAINDICATIONS APPLY. PLEASE CONSULT A SPECIALIST BEFORE USE.

For the full version of the medical instruction for Ademetionine PSK, please visit the open access website at https://grls.rosminzdrav.ru/Default.aspx